Inhibitory effects of the 5-HT1A receptor agonist buspirone on stress-induced hyperglycemia in mice: Involvement of insulin and a buspirone metabolite, 1-(2-pyrimidinyl)piperazine (1-PP)

Biological and Pharmaceutical Bulletin

Volumn 28, Issue 4, 2005, Pages 733-735

  Sugimoto, Yumi ^a   Takashima, Nozomu ^a   Noma, Toshiko ^a   Yamada, Jun ^a  

^a KOBE PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

1 (2 pyrimidinyl)piperazine; 5 HT 1A receptor; Anxiolytic; Buspirone; Glucose: insulin

Indexed keywords

1 (2 PYRIMIDINYL)PIPERAZINE; BUSPIRONE; GLUCOSE; INSULIN; SEROTONIN 1A AGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG METABOLISM; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; IMMOBILIZATION; INSULIN BLOOD LEVEL; INSULIN RELEASE; MALE; MOUSE; NONHUMAN; STRESS; TRANQUILIZING ACTIVITY;

ANIMALS; BUSPIRONE; HYPERGLYCEMIA; INSULIN; MALE; MICE; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN AGONISTS; STRESS;

EID: 21144445543     PISSN: 09186158     EISSN: None     Source Type: Journal    
DOI: 10.1248/bpb.28.733     Document Type: Article

References (21)

1. Deakin J., J. Psychopharmacol., 4 (Suppl.) S1-S5 (1998).
2. Deakin J. F. W., J. Phychopharmacol., 7, 283 (1993).
3. Briley M., Moret C., J. Clin. Neuropharmacol., 16, 24-35 (1993).
4. Axelord J., Reisine T. D., Science, 224, 452-459 (1983).
5. Chaouloff F., J Psychopharmacol., 14, 139-151 (2000).
6. Chaouloff F., Jeanrenaud B., J. Pharmacol. Exp. Ther., 243, 1159-1166 (1987).
7. Durcan M. J., Wozniak K. M., Linnoila M., Brit. J. Pharmacol., 102, 222-226 (1991).
8. Chaouloff F., Baudrie V., Laude D., Eur. J. Pharmacol., 177, 107-110 (1990).
9. Sugimoto Y., Yamada J., Kimura I., Watanabe Y., Horisaka K., Jpn. J. Pharmacol., 60, 145-148 (1992).
10. Chaouloff F., Baudrie V., Laude D., Naunyn-Schmiedeberg's Arch. Pharmacol., 341, 381-384 (1990).
11. Chaouloff F., Laude D., Baudrie V., Eur. J. Pharmacol., 185, 11-18 (1990).
12. Sugimoto Y., Takashima N., Noma T., Yamada J., J. Pharmacol. Sci., 93, 446-450 (2003).
13. Bialik R. J., Smythe J. W., Sardelis M., Roberts D. C. S., Brain Res., 502, 88-98 (1989).
14. Sugimoto Y., Noma T., Yamada J., Life Sci., 63, 1221-1226 (1998).
15. Groenink L., van der Gugten J., Verdouw P. M., Maes R. A., Olivier B., Eur. J. Pharmacol., 280, 185-193 (1995).
16. Groenink L., van der Gugten J., Zethof T. J., van der Heyden J. A., Olivier B., Pharmacol. Biochem. Behav., 54, 249-254 (1996).
17. Caccia S., Conti I., Vigano G., Garattini S., Pharmacology, 33, 46-51 (1986).
18. Gower A. J., Tricklebank M. D., Eur. J. Pharmacol., 155, 129-137 (1988).
19. Angel I., Bidet S., Langer S. Z., J. Pharmacol. Ther., 246, 1098-1103 (1988).
20. Nakadate T., Nakai T., Muraki T., Kato R., J. Pharmacol. Exp. Ther., 215, 226-230 (1988).
21. Yamada J., Sugimoto Y., Noma T., Life Sci., 66, 1213-1221 (2000).